



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control CCX-21-0198

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

8 Mei 2021 19.00

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id, immadoelhaq@gmail.com, mrezaarif@yahoo.com, bagus.sulistyono.1@gmail.com, rizkimz@gmail.com, atikarosada13@gmail.com, drcita.rosita@gmail.com, rahadian-i-s@fk.unair.ac.id

08-May-2021

Dear Dr. Wahyuhadi:

Your manuscript entitled "Active Immunotherapy Treatment for Glioblastoma: A Systematic Review and Meta-analysis of Phase II/III Randomized Controlled Trials" has been successfully submitted online and is presently being given full consideration for publication in Cancer Control.

Your manuscript ID is CCX-21-0198.

You have listed the following individuals as authors of this manuscript:

Wahyuhadi, Joni; Haq, Irwan; Arifianto, Muhammad; Sulistyono, Bagus; Meizikri, Rizki; Rosada, Atika; Prakoeswa, Cita; Susilo, Rahadian

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/ccx> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/ccx>.

As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID (<https://orcid.org/>). We encourage all authors and co-authors to use ORCID iDs during the peer review process. If you have not already logged in to your account on this journal's ScholarOne Manuscripts submission site in order to update your account information and provide your ORCID identifier, we recommend that you do so at this time by logging in and editing your account information. In the event that your manuscript is accepted, only ORCID iDs validated within your account prior to acceptance will be considered for publication alongside your name in the published paper as we cannot add ORCID iDs during the Production steps. If you do not already have an ORCID iD you may login to your ScholarOne account to create your unique identifier and automatically add it to your profile.

Thank you for submitting your manuscript to Cancer Control.

Sincerely,
Katie Willis
Cancer Control
ccx@sagepub.com



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control Update: Your article is under review - Manuscript ID CCX-21-0198

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

10 Juni 2021 07.47

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

09-Jun-2021

Dear Dr. Wahyuhadi:

We're writing to let you know that we have secured a review team for your manuscript entitled "Active Immunotherapy Treatment for Glioblastoma:

A Systematic Review and Meta-analysis of Phase II/III Randomized Controlled Trials" with manuscript ID CCX-21-0198 and it is now under review. We will reach out to you again once a decision has been made.

Thank you again for submitting to Cancer Control and let us know if you have any questions.

Sincerely,

Jennifer Lovick, PhD

Executive Editor, Cancer Control

Jennifer.Lovick@sagepub.com



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control Update: Your article is under review - Manuscript ID CCX-21-0198

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

1 Juli 2021 19.09

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

01-Jul-2021

Dear Dr. Wahyuhadi:

We're writing to let you know that we have secured a review team for your manuscript entitled "Active Immunotherapy Treatment for Glioblastoma:

A Systematic Review and Meta-analysis of Phase II/III Randomized Controlled Trials" with manuscript ID CCX-21-0198 and it is now under review. We will reach out to you again once a decision has been made.

Thank you again for submitting to Cancer Control and let us know if you have any questions.

Sincerely,

Jennifer Lovick, PhD

Executive Editor, Cancer Control

Jennifer.Lovick@sagepub.com

Cancer Control - Decision on Manuscript ID CCX-21-0198

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

10 Juli 2021 04.19

Balas Ke: Jennifer.Lovick@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

09-Jul-2021

Dear Dr. Wahyuhadi:

Manuscript ID CCX-21-0198 entitled "Active Immunotherapy Treatment for Glioblastoma: A Systematic Review and Meta-analysis of Phase II/III Randomized Controlled Trials" which you submitted to Cancer Control, has been reviewed. The comments of the reviewer(s) and editor(s) are included at the bottom of this letter.

We ask that you have your manuscript be proofread by a native English speaker. If you are unable to find a suitable individual to proofread your manuscript, SAGE Publishing offers a language editing service via Editage at an additional cost (<http://languageservices.sagepub.com/en/>). If you choose to use SAGE's language editing service, you may use the discount code CCX20 to receive 20% off.

Your revision is due on 07-Sep-2021. For your convenience, there is a calendar reminder attached to this email.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/ccx> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=da76412fcb5d42f8887f67c9346ca7df

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please highlight those areas that have undergone changes.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form that includes all the reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Cancer Control, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision by the deadline, please contact the editorial office to arrange a new deadline.

Once again, thank you for submitting your manuscript to Cancer Control and I look forward to receiving your revision.

Sincerely,
Jennifer Lovick, PhD

Executive Editor, Cancer Control

on behalf of Prof. Ulrich Ronellenfitsch
Section Editor, Cancer Control

Executive Editor Comments to Author:

Please check the following items about your manuscript. Provide responses to each of my points below and amend your manuscript accordingly (highlight the changes to your manuscript within the document by using bold or colored text).

- Have you reported your study according to the relevant Equator network guideline: e.g. PRISMA <https://www.equator-network.org/> ? If not, please do this now. You need to state in your Methods section that you have followed the relevant guideline (i.e. name the specific guideline) and cite it in your text.
- Ensure your manuscript contains all of the requirements for conducting a meta-analysis.
- Did you register your study with PROSPERO or INPLASY? If you did, please state this in our manuscript and include the registration number. **If you did not register with PROSPERO: you must register it now at the Research Registry: <https://www.researchregistry.com/> and state this in your manuscript with the registration number. Alternatively, you can register with INPLASY: <https://inplasy.com/> and state this in your manuscript with the registration number.**
- Was your search extensive or too restricted – i.e. did you search enough academic search systems (such as Google Scholar, MEDLINE, PubMed, Science Direct, Scopus, CNKI, etc) to ensure you included all relevant studies?
- Please confirm that fellow researchers may reproduce your results from the description given in your methods section. If you feel they can't, please improve your Methods section so that they can.
- Have you checked that you have sufficient studies in your analysis and that your choice of statistics is correct?
- Are there other meta-analyses already published? You need to discuss/cite these (especially any recent ones) and say what your analysis adds to the literature.

Section Editor's Comments to Author:

Section Editor: Ronellenfitsch, Ulrich
Comments to the Author:

In addition to the peer reviewer comments, I suggest that the manuscript undergoes proofreading by a native English speaker prior to re-submission.

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author

This meta-analysis checked the effect of active immunotherapy in patients with GBM. According to PRISMA, the study was conducted. However, by a systematic search, only 6 studies were included for quantitative synthesis. According to inclusion and exclusion criteria, we found some studies which didn't included in this meta-analysis. Hope that the author can search the literature better. This will increase the reliability of the results. In additions, the title of this meta-analysis needs to further revise.

A minor comment related to the writing is that there are a number of grammatical errors throughout the manuscript.

Reviewer: 2

Comments to the Author

In this systematic Reviews and Meta-Analysis, authors reported parameters are OS, PFS, AEs, post treatment KPS and two-year mortality from database searched from PubMed, Cochrane, Scopus and clinicaltrials.gov. And they concluded that active immunotherapy benefit survival rate in patients with GBM. Here are some comments for improvement of this study.

1. In the line 57 of page 4, ("active immunotherapy" OR "targeted therapy" OR "dendritic cell vaccine" OR "peptide vaccine" OR "DNA vaccine" OR "Viral vector based vaccine" OR "antigen non-specific vaccines" OR "autologous tumor cell therapy"). Why not include CART? Or immune RNA if possible.
2. In the line 3 of page 5, (glioblastoma OR GBM OR "high grade glioma" OR HGG). "Astrocytomas, Grade IV" was missed. Those mistakes make the conclusion not convincing when data are incomplete.
3. (glioblastoma OR GBM OR "high grade glioma" OR HGG). Actually, "high grade glioma" > glioblastoma. The title should be corrected.
4. Some critical factors related immunity should be taken into account, such as age, complications, (tuberculosis, AIDS), chemotherapy, and so on.
5. This study need to renew the latest data form all related database and the reference.
6. Since the data is not completed, the conclusion is not convincing.

7. there are much gramma mistakes.

(1) Glioblastoma multiforme (GBM) accounts for approximately 60-70% of gliomas and 15% of primary brain tumors.

(2) Despite of the advances in surgery and chemoradiotherapy, survival rates within 2-, 3-, and 5-years in population-based study of GBM patients were 18%, 11% and 4% respectively. Active immunotherapy is a new area of research that may be a successful treatment option.

(3) Active immunotherapy shows promising results in terms of survival rate in patients with GBM and could be the future of the treatment of GBM.

(4) and temozolomide (TMZ), does not warrant survival nor avoid recurrence of GBM.2,3

(5) Survival rates within 2-, 3-, and 5-years in a population-based study of GBM patients were 18%, 11% and 4% respectively.4

.....

 **Author Due Date Cancer Control.ics**
1K

Reminder: Revised Manuscript CCX-21-0198 due in 2 weeks - Cancer Control

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

25 Agustus 2021 14.06

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

25-Aug-2021

Dear Dr. Wahyuhadi:

Recently, you received a decision on Manuscript ID CCX-21-0198, entitled "Active Immunotherapy Treatment for Glioblastoma:

A Systematic Review and Meta-analysis of Phase II/III Randomized Controlled Trials." The manuscript and decision letter are located in your Author Center at <https://mc.manuscriptcentral.com/ccx>.

This e-mail is simply a reminder that your revision is due in two weeks. If it is not possible for you to submit your revision within two weeks, please let the editorial office know as they may be able to arrange a new deadline.

As a reminder, you may click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=1dc6430576bc49cbb351b20698c59446

When submitting your revised manuscript, you will be asked to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form.
- an author's response that includes all reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

Sincerely,
Cancer Control Editorial Office
ccx@sagepub.com



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control CCX-21-0198.R1

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

1 September 2021 12.26

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id, immadoelhaq@gmail.com, mrezaarif@yahoo.com, bagus.sulistyono.1@gmail.com, rizkimz@gmail.com, atikarosada13@gmail.com, drcita.rosita@gmail.com, rahadian-i-s@fk.unair.ac.id

01-Sep-2021

Dear Dr. Wahyuhadi:

Your revised manuscript entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" has been successfully submitted online and is presently being given full consideration for publication in Cancer Control.

Your manuscript ID is CCX-21-0198.R1.

You have listed the following individuals as authors of this manuscript:

Wahyuhadi, Joni; Haq, Irwan; Arifianto, Muhammad; Sulistyono, Bagus; Meizikri, Rizki; Rosada, Atika; Prakoeswa, Cita; Susilo, Rahadian

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/ccx> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/ccx>.

As part of our commitment to ensuring an ethical, transparent, and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID (<https://orcid.org/>). We encourage all authors and co-authors to use ORCID iDs during the peer review process. The ORCID iD profile should include as much information as possible regarding work experience, education history, and publication history. If you have not already logged in to your account on this journal's ScholarOne Manuscripts submission site in order to update your account information and provide your ORCID identifier, we recommend that you do so at this time by logging in and editing your account information. The journal strongly encourages providing as much information as possible in the ORCID profile. In the event that your manuscript is accepted, only ORCID iDs validated within your account prior to acceptance will be considered for publication alongside your name in the published paper as we cannot add ORCID iDs during the Production steps. If you do not already have an ORCID iD you may login to your ScholarOne account to create your unique identifier, complete your ORCID profile, and automatically add it to your ScholarOne account profile. If your ORCID account does not match your SAGE Track account, it will be removed.

Thank you for submitting your manuscript to Cancer Control.

Sincerely,
Cancer Control Editorial Office
Cancer Control
ccx@sagepub.com

Cancer Control - Decision on Manuscript ID CCX-21-0198.R1

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

13 Oktober 2021 00.45

Balas Ke: Jennifer.Lovick@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

12-Oct-2021

Dear Dr. Wahyuhadi:

Manuscript ID CCX-21-0198.R1 entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" which you submitted to Cancer Control, has been reviewed. The comments of the reviewer(s) and editor(s) are included at the bottom of this letter.

Your revision is due on 11-Dec-2021. For your convenience, there is a calendar reminder attached to this email.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/ccx> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=18c956c29f18422297d362d26cb1b345

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please highlight those areas that have undergone changes.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form that includes all the reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Cancer Control, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision by the deadline, please contact the editorial office to arrange a new deadline.

Once again, thank you for submitting your manuscript to Cancer Control and I look forward to receiving your revision.

Sincerely,
Ulrich Ronellenfitsch, MD
Assistant Professor of Surgery
University Hospital Halle, Halle, Germany
ulrich.ronellenfitsch@uk-halle.de
Section Editor, Cancer Control

Jennifer Lovick, PhD
Executive Editor
Cancer Control
Jennifer.Lovick@sagepub.com

Executive Editor

Comments to the Author:

Please thoroughly respond to the reviewer's concerns. If they cannot be sufficiently addressed, we will not consider your manuscript further. I suggest that you consider further how the findings can have practical significance. We strongly recommend that you have your manuscript be proofread by a native English speaker. If you are unable to find a suitable individual to proofread your manuscript, SAGE Publishing offers a language editing service via Editage at an additional cost (<http://languageservices.sagepub.com/en/>). If you choose to use SAGE's language editing service, you may use the discount code CCX20 to receive 20% off.

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author

This meta-analysis reports the role of active immunotherapy in glioblastoma. The analysis method of this article is correct. The conclusion is acceptable. However, the article is of poor practical significance. A minor comment related to the writing is that there are a number of grammatical errors throughout the manuscript.

 **Author Due Date Cancer Control.ics**
1K

Cancer Control CCX-21-0198.R2

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

26 Oktober 2021 10.07

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id, immadoelhaq@gmail.com, mrezaarif@yahoo.com, bagus.sulistyono.1@gmail.com, rizkimz@gmail.com, atikarosada13@gmail.com, drcita.rosita@gmail.com, rahadian-i-s@fk.unair.ac.id

25-Oct-2021

Dear Dr. Wahyuhadi:

Your revised manuscript entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" has been successfully submitted online and is presently being given full consideration for publication in Cancer Control.

Your manuscript ID is CCX-21-0198.R2.

You have listed the following individuals as authors of this manuscript:

Wahyuhadi, Joni; Haq, Irwan; Arifianto, Muhammad; Sulistyono, Bagus; Meizikri, Rizki; Rosada, Atika; Prakoeswa, Cita; Susilo, Rahadian

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc.manuscriptcentral.com/ccx> and edit your user information as appropriate.

You can also view the status of your manuscript at any time by checking your Author Center after logging in to <https://mc.manuscriptcentral.com/ccx>.

As part of our commitment to ensuring an ethical, transparent, and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID (<https://orcid.org/>). We encourage all authors and co-authors to use ORCID iDs during the peer review process. The ORCID iD profile should include as much information as possible regarding work experience, education history, and publication history. If you have not already logged in to your account on this journal's ScholarOne Manuscripts submission site in order to update your account information and provide your ORCID identifier, we recommend that you do so at this time by logging in and editing your account information. The journal strongly encourages providing as much information as possible in the ORCID profile. In the event that your manuscript is accepted, only ORCID iDs validated within your account prior to acceptance will be considered for publication alongside your name in the published paper as we cannot add ORCID iDs during the Production steps. If you do not already have an ORCID iD you may login to your ScholarOne account to create your unique identifier, complete your ORCID profile, and automatically add it to your ScholarOne account profile. If your ORCID account does not match your SAGE Track account, it will be removed.

Thank you for submitting your manuscript to Cancer Control.

Sincerely,
Cancer Control Editorial Office
Cancer Control
ccx@sagepub.com



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control - CCX-21-0198.R2 has been unsubmitted

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

28 Oktober 2021 09.47

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

27-Oct-2021

Dear Dr. Wahyuhadi:

Your manuscript, CCX-21-0198.R2, entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" has been unsubmitted to Cancer Control. It was unsubmitted for the following reason(s):

The main text file and response letter should be anonymous. All author, co-author, acknowledgement, funding, Declarations, Authors' Contributions and conflict of interest should be updated as a separate title page in order to avoid any anonymity issue. I would request you to kindly remove author information from response letter.

To resubmit, please login to <https://mc.manuscriptcentral.com/ccx> and click on the Author Center link. Click the 'Unsubmitted and Manuscripts in Draft' link in the Author Dashboard, find the returned manuscript, and select the 'Continue' link. You may make the necessary changes and submit the manuscript again.

Please contact the Editorial Office if you have further questions.

Sincerely,
Cancer Control Editorial Office

Reminder: Revised Manuscript CCX-21-0198.R1 due in 2 weeks - Cancer Control

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

28 November 2021 13.16

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

28-Nov-2021

Dear Dr. Wahyuhadi:

Recently, you received a decision on Manuscript ID CCX-21-0198.R1, entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis." The manuscript and decision letter are located in your Author Center at <https://mc.manuscriptcentral.com/ccx>.

This automatic e-mail is simply a reminder that your revision is due in two weeks. If it is not possible for you to submit your revision within two weeks, please let the editorial office know as they may be able to arrange a new deadline.

As a reminder, you may click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=7beaf5d06b494847a1d7024d8d4e381c

When submitting your revised manuscript, you will be asked to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form.
- an author's response that includes all reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

Sincerely,
Cancer Control Editorial Office
ccx@sagepub.com
Cancer Control Editorial Office

RE: Cancer Control: CCX-21-0198.R1

2 pesan

Jennifer Lovick <Jennifer.Lovick@sagepub.com>

14 Desember 2021 23.37

Kepada: "joniwahyuhadi@fk.unair.ac.id" <joniwahyuhadi@fk.unair.ac.id>, ccx <ccx@sagepub.com>

Dear Joni,

Thank you for writing and letting us know. The deadline to submit the revision had passed. I have re-opened the system for you so that you can complete the re-submission process. If you continue to have issues accessing the site, please let me know.

Best,

Jennifer

Jennifer Lovick, PhD

Executive Editor

Cancer Control

Jennifer.Lovick@sagepub.com

From: Cancer Control <onbehalf@manuscriptcentral.com>**Sent:** Tuesday, December 14, 2021 3:49 AM**To:** ccx <ccx@sagepub.com>**Cc:** Jennifer Lovick <Jennifer.Lovick@sagepub.com>**Subject:** Cancer Control: CCX-21-0198.R1**[EXTERNAL]**Dear *Cancer Control* Editorial Office:

We are sorry for being unable to submit the manuscript before the due date. We have completed the requirements needed and tried several times to re-submit our revision, however the system rejected it so we could not submit it. Please let us know if there is any other requirement that we have not completed. We hope that we still can submit our systematic review and meta-analysis in *Cancer Control*.

Thank you very much.

Sincerely,

Joni Wahyuhadi

Department of Neurosurgery

Soetomo General Academic Hospital

Faculty of Medicine Airlangga University

Manuscript ID: CCX-21-0198.R1

Manuscript Title: Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis

wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

15 Desember 2021 14.46

Kepada: Jennifer Lovick <Jennifer.Lovick@sagepub.com>

Dear Jennifer,

Thank you for the opportunity to re-submit our systematic review and meta-analysis in Cancer Control. We would like to let you know that we have just successfully re-submitted our revision. Please let us know if there is any other thing that we still need to provide, other than what we have submitted. We are looking forward to hearing from Cancer Control Editorial Board.

Thank you very much.

Sincerely,

Joni Wahyuhadi

Department of Neurosurgery

Soetomo General Academic Hospital

Faculty of Medicine Airlangga University

[Kutipan teks disembunyikan]

Cancer Control - Decision on Manuscript ID CCX-21-0198.R2

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

4 Januari 2022 03.26

Balas Ke: Jennifer.Lovick@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

03-Jan-2022

Dear Dr. Wahyuhadi:

Manuscript ID CCX-21-0198.R2 entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" which you submitted to Cancer Control, has been reviewed. The comments of the reviewer(s) and editor(s) are included at the bottom of this letter.

Your revision is due on 17-Jan-2022. For your convenience, there is a calendar reminder attached to this email.

To revise your manuscript, log into <https://mc.manuscriptcentral.com/ccx> and enter your Author Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a Revision." Your manuscript number has been appended to denote a revision.

You may also click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=cf3ede33f62b4afa9e7cad76fc54fd9f

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please highlight those areas that have undergone changes.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form that includes all the reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to Cancer Control, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision by the deadline, please contact the editorial office to arrange a new deadline.

Once again, thank you for submitting your manuscript to Cancer Control and I look forward to receiving your revision.

Sincerely,
Ulrich Ronellenfitsch, MD
Assistant Professor of Surgery
University Hospital Halle, Halle, Germany
ulrich.ronellenfitsch@uk-halle.de
Section Editor, Cancer Control

Jennifer Lovick, PhD

Executive Editor
Cancer Control
Jennifer.Lovick@sagepub.com

Reviewer(s)' Comments to Author:

Reviewer: 3

Comments to the Author
(There are no comments.)

Reviewer: 4

Comments to the Author

Comment 1:

The overriding goal of this review article is to summarize the clinical evidence regarding survival benefits of immunotherapy for glioblastoma patients. The authors have collected the huge information in glioblastoma immunotherapies and particularly they highlighted the notable outcomes assessing immunotherapeutic efficiency in GBM patients.

Comment 2:

Authors have used very straightforward phrase to make it simple to understand for readers. However, the writing here is not attractive to readers to understand subject and niche of the information.

Comment 3:

Immunotherapeutic agents particularly in application for glioblastoma are very hot but debatable topic currently. Although the paper is overall written well, I am not sure this paper significantly adds new value to what we already know. A quick literature search in PubMed revealed large amount of review articles regarding "immunotherapy in glioblastoma" and quite a lot of them already described and analyzed promising results of immunotherapy in GBM patients. In order to add new value compared to already published review papers, the authors should provide more in-depth discussion/conclusion and their own opinion to highlight possible future strategies for effective treatment of glioblastoma (GBM) with immunotherapies rather than just gathering examples and doing meta-analysis.

Comment 4:

It will be better if the authors also provide some future strategies to ameliorate the efficiency of immunotherapy and facilitate clinical translation to address the unmet clinical need of glioblastoma.

Comment 5:

Although adaptive immune checkpoints played an important role in the fighting of tumor cells, the overall response rate is normally less than 20%.

Comment 6:

Also, there is a new trend that focus on innate immune checkpoint such as CD47, which has emerged as next generation immunotherapy. However, the author did not mention any information regarding different kinds of immunotherapies in this review. Therefore, it would be appreciated if you could give a special explanation of the immune checkpoint inhibitors (eg: PD1, PDL1, CTLA4, IDO, and CD73) that were applied in the collected studies.

Reviewer: 5

Comments to the Author

The authors present a systematic review and meta-analysis of RCTs related to active immunotherapy in glioblastoma. The results are heterogeneous as they encompass both newly diagnosed and recurrent glioblastoma. Additionally, trial criteria are quite mixed. All these limit the applicability to clinical practice. Further, the conclusions are not sound. It would be fine to suggest a "trend" toward improvement - but the statistics reveal that there is no OS or PFS benefit (CI including 1). Therefore, to say that it is "promising" or "Better results" is absolutely misleading. There is a statistical trend, but clearly the results are NOT better given that there is no statistical benefit. Finally, the manuscript still needs extensive editing for English language as much of the language remains confusing.

 **Author Due Date Cancer Control.ics**
1K

Reminder: Revised Manuscript CCX-21-0198.R2 due in 2 weeks - Cancer Control

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

4 Januari 2022 13.27

Balas Ke: ccx@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

04-Jan-2022

Dear Dr. Wahyuhadi:

Recently, you received a decision on Manuscript ID CCX-21-0198.R2, entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis." The manuscript and decision letter are located in your Author Center at <https://mc.manuscriptcentral.com/ccx>.

This automatic e-mail is simply a reminder that your revision is due in two weeks. If it is not possible for you to submit your revision within two weeks, please let the editorial office know as they may be able to arrange a new deadline.

As a reminder, you may click the below link to start the revision process (or continue the process if you have already started your revision) for your manuscript. If you use the below link you will not be required to login to ScholarOne Manuscripts.

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/ccx?URL_MASK=a4dba8f958074e379339bd2cd45be696

When submitting your revised manuscript, you will be asked to respond to the comments made by the reviewer(s) and editor(s) in the space provided. You should complete the Author Response to Reviewers form (available here: <https://sagepub.com/response-to-reviewers-template>), answering point-by-point the questions raised and referencing the page numbers where the changes are implemented.

In summary, you will need to submit the following:

- a clean, revised main document in doc. or docx. (blinded)
- a highlighted, revised main document in doc. or docx. (blinded)
- a completed Author Response to Reviewers form.
- an author's response that includes all reviewer comments you received in full and answers the questions raised by reviewers in doc. or docx. (blinded)

Sincerely,
Cancer Control Editorial Office
ccx@sagepub.com
Cancer Control Editorial Office



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Cancer Control - Decision on Manuscript ID CCX-21-0198.R3

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

25 Januari 2022 01.57

Balas Ke: Jennifer.Lovick@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

24-Jan-2022

Dear Dr. Wahyuhadi:

It is a pleasure to accept your manuscript entitled "Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis" in its current form for publication in Cancer Control.

Thank you for your fine contribution. On behalf of the Editors of Cancer Control, we look forward to your continued contributions to the Journal.

Sincerely,
Ulrich Ronellenfitsch, MD
Assistant Professor of Surgery
University Hospital Halle, Halle, Germany
ulrich.ronellenfitsch@uk-halle.de
Section Editor, Cancer Control

Jennifer Lovick, PhD
Executive Editor
Cancer Control
Jennifer.Lovick@sagepub.com

Cancer Control Next steps for your article (CCX-21-0198.R3)

1 pesan

Cancer Control <onbehalf@manuscriptcentral.com>

25 Januari 2022 17.38

Balas Ke: openaccess@sagepub.com

Kepada: joniwahyuhadi@fk.unair.ac.id

Cc: joniwahyuhadi@fk.unair.ac.id, immadoelhaq@gmail.com, mrezaarif@yahoo.com, bagus.sulistyono.1@gmail.com, rizkimz@gmail.com, atikarosada13@gmail.com, drcita.rosita@gmail.com, rahadian-i-s@fk.unair.ac.id

25-Jan-2022

Dear Dr. Joni Wahyuhadi,

CCX-21-0198.R3 - Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis

Your manuscript will shortly be exported to SAGE's production system. The next steps are as follows: -

1. You will receive an email from openaccess@sagepub.com asking you to complete the open access process for your article through the SAGE Open Access Portal in the next 7 working days
2. Follow the link in the email to: -
 - View the article processing charge (APC)* due for your article. The current APC rate can be found on the journal's SAGE homepage. If you have been informed that your article will receive a discount or waiver, you will be able to see that it has been applied in the portal
 - Complete the Open Access Contributor Agreement so that SAGE can proceed with the publication of your article
 - Pay the open access processing charge (APC)*, if applicable. You may pay the APC yourself or nominate another bill payer to take responsibility for the payment through the portal. Payment can be made via credit/debit card or via wire/bank transfer
3. You will receive proofs of your article from the journal's Production Editor. Please allow at least 2 weeks to receive proofs. These should be checked thoroughly and returned promptly.

Once the steps have been completed, your article will be published open access on the journal website.

Please look out for the next email from openaccess@sagepub.com asking you to complete the open access process and act promptly. We are unable to proceed with publication of your article until the steps have been completed.

Please only contact us if you have not received the open access process email after 7 working days have passed.

With best wishes,

SAGE Open Access Team

*The APC is subject to tax where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when entering the billing details. Please see further details here: <https://us.sagepub.com/en-us/nam/faqs#tax>. The currency in which the APC is charged is determined by the geographical region of the corresponding author and cannot be changed by the payer of the APC.

Complete the Open Access process for your article 10.1177/10732748221079474 now

1 pesan

openaccess@sagepub.com <openaccess@sagepub.com>

27 Januari 2022 17.34

Kepada: joniwahyuhadi@fk.unair.ac.id

Cc: immadoelhaq@gmail.com, mrezaarif@yahoo.com, bagus.sulistyono.1@gmail.com, rizkimz@gmail.com, atikarosada13@gmail.com, drcita.rosita@gmail.com, rahadian-i-s@fk.unair.ac.id

Complete the Open Access process for your article now

Dear Joni Wahyuhadi,

Congratulations on the acceptance of your paper *Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-analysis* (DOI: 10.1177/10732748221079474/ ID: CCX-21-0198.R3) in Cancer Control.

Cancer Control is a Gold Open Access journal, in which all papers are made freely available and published with an Open Access license. In order to proceed with the publication of your article, you need to select the appropriate OA license type.

Select license type

Please note, to proceed with publication, an article processing charge (APC) is payable by you or a bill payer of your choice: 2,300.00 USD (subject to tax where applicable). No production work will begin on your paper until the Open Access steps have been completed. To avoid delay, please complete the steps as soon as possible.

Visit [SAGE's Open Access Portal](#) to learn more and choose your license.

Best wishes,

SAGE Publishing Open Access Team

openaccess@sagepub.com

SAGE Offices:

Los Angeles: 2455 Teller Rd Thousand Oaks, CA 91320, USA

London: 1 Oliver's Yard, 55 City Road, London, EC1Y 1SP, UK. Registration No. 1017514

New Delhi: B-1/I-1, Mohan Cooperative Industrial Estate, Mathura Road, Post Bag 7, New Delhi 110 044, India

Singapore: 18 Cross Street #10-10/11/12, China Square Central, Singapore 048423

Washington, DC: 2600 Virginia Avenue NW, Suite 600, Washington, DC, 20037, USA

Melbourne: Level 20, 114 William Street Melbourne, VIC 3000, Australia

[About SAGE](#)

[Privacy policy](#)

WF2 GEA1

CCX | 1079474 | Cancer Control | reference id CCX-21-0198

1 pesan

ccx_sagepub@tnq.co.in <ccx_sagepub@tnq.co.in>
Kepada: joniwahyuhadi@fk.unair.ac.id
Cc: ccx_sagepub@tnq.co.in, ccxprod@sagepub.com

20 Februari 2022 12.16

Dear Dr. Joni Wahyuhadi,

This proof is sent to you on behalf of SAGE Publishing.

Thank you for publishing with the Cancer Control. The proof for your upcoming publication is ready for review via the link below. You will find instructions on the start page about how to make corrections directly on screen or through PDF.

Please use one of the following browser versions to access your proof:

- Firefox 45.0+
- Google Chrome 50.0+
- Safari 10.0+

<https://sage.proofcentral.com/en-us/landing-page.html?token=3552a9ae07475c19994fc04076d053>

We ask that you check the accuracy of the typesetting, copyediting, completeness, correctness of the text, tables, figures and address all the queries. Please make sure that you check all author names and addresses carefully. Particular attention should also be paid to tables, figures, equations, and any mathematical or Non-English symbols/characters.

You can save and return to your article at any time during the correction process. Once you make corrections and hit the SUBMIT button, you can no longer make further corrections. If multiple authors are expected to make corrections, each author should click the SAVE button when done. Please note that clicking SUBMIT will prevent all authors from making additional corrections.

Kindly respond within 48 hours (OR 2 working days), even if you have no corrections and do not hesitate to contact me if you have any queries.

Any colour figures have been incorporated for the online version only. Colour printing in the journal can be arranged for a charge. Please contact me for further details

We look forward to your response.

Sincerely,
Gokul Ganesh Kumaravel
Project Manager
E-mail: ccx_sagepub@tnq.co.in
SAGE Publishing
www.sagepublishing.com



wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Reminder : CCX | 1079474 | Cancer Control | reference id CCX-21-0198

3 pesan

ccx_sagepub@tnq.co.in <ccx_sagepub@tnq.co.in>

23 Februari 2022 08.30

Kepada: joniwahyuhadi@fk.unair.ac.id

Cc: ccx_sagepub@tnq.co.in

Dear Dr. Joni Wahyuhadi,

Please note that we have not yet received your proof corrections or your approval to publish the article without change. Kindly share your approval or submit the corrections to avoid further delay in publication of your article.

Please click on the link below to access your proofs and the instructions for returning your corrections.

<https://sage.proofcentral.com/en-us/landing-page.html?token=3552a9ae07475c19994fc04076d053>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser.

If you have already returned your corrections within the past 48 hours, please ignore this reminder.

Please note that once we receive your corrections, further amendments will no longer be possible.

Any colour figures have been incorporated for the online version only. Colour printing in the journal can be arranged for a charge. Please contact me for further details

Sincerely,

Gokul Ganesh Kumaravel

Project Manager

E-mail: ccx_sagepub@tnq.co.in

SAGE Publishing

www.sagepublishing.com

wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

23 Februari 2022 12.05

Kepada: ccx_sagepub@tnq.co.in

Dear Editor,

Thank you for your email. We have made several changes that have been waiting for approval. However, we still have difficulties in updating and adding other authors' ORCID ID. Please let us know how to edit and add other authors orchid id.

Thank you.

Regards,

Joni Wahyuhadi

Director of Dr. Soetomo General Academic Hospital

[Kutipan teks disembunyikan]

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>

23 Februari 2022 12.30

Kepada: wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

Dear Dr. Joni Wahyuhadi,

Thank you so much for the email.

Unfortunately, I am unable to add in the additional ORCID iD's/ORCID corrections at this stage.

Before a paper comes to us in Production, an ORCID must be validated in order for us to publish. ORCID iDs undergo rigorous validation within the submission system and so once the accepted article enters Production we are unable to add or amend ORCID iDs after acceptance. I am sorry that we will be unable to add in those details now.

[Kutipan teks disembunyikan]

Disclaimer: The entire content of this email message, including any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the named addressee or part of the entity, you should not disseminate, distribute, or copy this email. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing, or taking any action in reliance on the contents of this information is strictly prohibited.

Reminder : CCX | 1079474 | Cancer Control | reference id CCX-21-0198

3 pesan

ccx_sagepub@tnq.co.in <ccx_sagepub@tnq.co.in>
Kepada: joniwahyuhadi@fk.unair.ac.id
Cc: ccx_sagepub@tnq.co.in

25 Februari 2022 09.15

Dear Dr. Joni Wahyuhadi,

Please note that we have not yet received your proof corrections or your approval to publish the article without change. Kindly share your approval or submit the corrections to avoid further delay in publication of your article.

Please click on the link below to access your proofs and the instructions for returning your corrections.

<https://sage.proofcentral.com/en-us/landing-page.html?token=3552a9ae07475c19994fc04076d053>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser.

If you have already returned your corrections within the past 24 hours, please ignore this reminder.

Please note that once we receive your corrections, further amendments will no longer be possible.

Any colour figures have been incorporated for the online version only. Colour printing in the journal can be arranged for a charge. Please contact me for further details

Sincerely,
Gokul Ganesh Kumaravel
Project Manager
E-mail: ccx_sagepub@tnq.co.in
SAGE Publishing
www.sagepublishing.com

wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>
Kepada: ccx_sagepub@tnq.co.in

14 Maret 2022 09.02


Dear Editor,

We have completed our proof correction through that link, however we still could not submit. Everytime we submitted, there was note saying:

"There are uncited items in these sections: Footnote. Click OK to return to the editor. Then click Show Uncited in the corresponding widget to view the uncited items."

Please let us know how to proceed. Thank you.

[Kutipan teks disembunyikan]



Screen Shot 2022-03-07 at 17.19.53.png
3591K

CCX, SAGEPUP (TNQ) <ccx_sagepub@tnq.co.in>
Kepada: wahyuhadi Joni <joniwahyuhadi@fk.unair.ac.id>

14 Maret 2022 15.28

Dear Dr. Joni Wahyuhadi,

You can please disregard the message for uncited footnotes and click the “Cancel, Ignore” button to submit the corrections.

[Kutipan teks disembunyikan]

Disclaimer: The entire content of this email message, including any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not the named addressee or part of the entity, you should not disseminate, distribute, or copy this email. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing, or taking any action in reliance on the contents of this information is strictly prohibited.